PRTA - Prothena Corporation plc
| Previous Close | 11.71 |
| Open | 11.59 |
| Bid | 11.57 x 1400 |
| Ask | 11.61 x 900 |
| Day's Range | 11.39 - 11.73 |
| 52 Week Range | 10.43 - 46.14 |
| Volume | 90,930 |
| Avg. Volume | 497,239 |
| Market Cap | 462.02M |
| Beta (3Y Monthly) | 3.79 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.61 |
| Earnings Date | Feb 12, 2019 - Feb 18, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.57 |
Zacks•4 days agoImplied Volatility Surging for Prothena (PRTA) Stock Options
Prothena (PRTA) needs investors to pay close attention to the stock based on moves in the options market lately.
- Zacks•8 days ago
Prothena (PRTA) Down 12.3% Since Last Earnings Report: Can It Rebound?
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks•last month
Prothena (PRTA) Reports Narrower-Than-Expected Loss in Q3
Prothena (PRTA) posts narrower-than-expected loss in the third quarter. With the failure of lead drug, NEOD001, the focus is now on its mid-stage candidate, prasinezumab.
- Zacks•last month
Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of 33.33% and -2.67%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
Prothena: 3Q Earnings Snapshot
The Dun Laoghaire, Ireland-based company said it had a loss of 62 cents per share. Losses, adjusted for restructuring gains, came to 70 cents per share. The results exceeded Wall Street expectations. The ...
- GlobeNewswire•last month
Prothena Reports Third Quarter 2018 Financial Results and Provides R&D Update
Net cash used in operating and investing activities was $33.7 million in the third quarter and $7.5 million in the first nine months of 2018; quarter-end cash and restricted.
- GlobeNewswire•last month
Prothena to Report Third Quarter 2018 Financial Results on November 6
Prothena Corporation plc (PRTA), a clinical-stage neuroscience company, will announce financial results for the third quarter and first nine months of 2018 on November 6, 2018 after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on November 6. Prothena Corporation plc is a clinical-stage neuroscience company focused on the discovery and development of novel therapies with the potential to fundamentally change the course of progressive, life-threatening diseases.
- GlobeNewswire•2 months ago
Factors of Influence in 2018, Key Indicators and Opportunity within 1-800 FLOWERS.COM, Bojangles', Prothena Corporation plc, Lydall, Daktronics, and ServiceSource International — New Research Emphasizes Economic Growth
NEW YORK, Oct. 16, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Zacks•2 months ago
Celgene's Otezla Meets Goal in Scalp Plaque Psoriasis Study
Celgene's (CELG) efforts to expand psoriasis drug, Otezla gets a boost as the late-stage study for the indication of plaque psoriasis of the scalp meets primary endpoint.
- Zacks•2 months ago
Are Options Traders Betting on a Big Move in Prothena (PRTA) Stock?
Investors need to pay close attention to Prothena (PRTA) stock based on the movements in the options market lately.
- Business Wire•3 months ago
September 17th Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Prothena Corporation plc (PRTA)
National securities litigation law firm Glancy Prongay & Murray LLP (“GPM”) reminds investors of the September 17, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Prothena Corporation plc (“Prothena” or the “Company”) (NASDAQ: PRTA) securities between October 15, 2015 and April 20, 2018, inclusive (the “Class Period”). Investors suffering losses on their Prothena investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to shareholders@glancylaw.com.
- Zacks•3 months ago
Why Is Prothena (PRTA) Up 8.2% Since Last Earnings Report?
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire•3 months ago
EQUITY NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Prothena Corporation plc – PRTA
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Prothena Corporation plc from October 15, 2015 through April 20, 2018, both dates inclusive .
- Business Wire•4 months ago
The Law Offices of Howard G. Smith Reminds Investors of Extended Lead Plaintiff Deadline in the Class Action Lawsuit Against Prothena Corporation plc (PRTA)
Law Offices of Howard G. Smith reminds investors of the September 17, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Prothena Corporation plc (“Prothena” or the “Company”) (NASDAQ: PRTA) securities between October 15, 2015 and April 20, 2018, inclusive (the “Class Period”). Prothena investors have until September 17, 2018 to file a lead plaintiff motion.
- Zacks•4 months ago
Is Celgene Set to See Improved Results in the Second Half?
After a series of pipeline setbacks, things are looking better for biotech bigwig Celgene (CELG) with positive data read-outs and an increase in guidance.
- Zacks•4 months ago
Prothena (PRTA) Q2 Earnings Lag Estimates, Pipeline in Focus
Prothena (PRTA) posts wider-than-expected loss in the second quarter. With the failure of lead drug, NEOD001, the focus is now mainly on its mid-stage candidate, prasinezumab.
- Zacks•4 months ago
Prothena (PRTA) Reports Q2 Loss, Tops Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of -11.36% and 29.77%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•4 months ago
Prothena: 2Q Earnings Snapshot
The Dun Laoghaire, Ireland-based company said it had a loss of $1.50 per share. Losses, adjusted for restructuring costs, came to 98 cents per share. The results did not meet Wall Street expectations. ...
